Sumant Kulkarni

Michael Okunewitch

Rudy Li

Brian Abrahams

Charles Duncan

Marc Goodman

Christopher Chen

Elias Georgas

Gavin Clark-Gartner

Jay Olson

Joel Beatty

Luis Santos

Patrick Trucchio

Pete Stavropoulos

François Brisebois

James Nevin

Jason McCarthy

Madhumita Yennawar

- MindMed's MM120 (LSD), a **serotonin 2A agonist**, is being developed for **Generalized Anxiety Disorder (GAD)**, an indication affecting an estimated **10% of the U.S. adult population (26 million people)**, where the last approval was in 2007.  **[1813814_2147414_0]** 
- The Phase 2b study of MM120 for GAD showed a **7.7 unit improvement** over placebo at 12 weeks with a single dose, which is more than double typical approved drugs, and achieved a **48% remission rate** and **65% response rate** at 12 weeks in the **100 microgram arm**.  **[1813814_2147414_4]** 
- Adverse events were primarily limited to the day of dosing, with the **100 microgram dose** resulting in a "remarkably benign" patient experience and a reduced monitoring time from 12 hours in Phase 2 to **8 hours** in Phase 3.  **[1813814_2147414_2]** **[1813814_2147414_3]** 
- MM120 has received **Breakthrough Therapy Designation** from the FDA, and MindMed is comfortable with its Phase 3 program design for both GAD and Major Depressive Disorder (MDD).  **[1813814_2147414_5]**

Mind Medicine (MindMed) Discusses MM120 Phase 2b GAD Data and Phase 3 Plans

Mind Medicine (MindMed) (MNMD)